ReviewHuman

Current pharmacological approaches and potential future therapies for Celiac disease

European journal of pharmacology, 2021 Oct 15. Kulkarni A, Patel S, Khanna D and 1 others.

Study type

Review

Subjects

Human participants (PubMed MeSH: Humans)

Journal

European journal of pharmacology

Published

2021 Oct 15

PubMed

PMID 34418405 ↗

DOI

10.1016/j.ejphar.2021.174434 ↗

Where PepCue cites this

This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.

Larazotide →

Indexed under

MeSH terms assigned by the National Library of Medicine.

Autoimmune DiseasesCeliac DiseaseClinical Trials as TopicDiet, Gluten-FreeGlutensHumansIntestinal MucosaOligopeptidesPeptide HydrolasesTight Junctions

Other papers on Larazotide

Randomized controlled trial · 2015

Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial

Journal article · 2021

Larazotide acetate induces recovery of ischemia-injured porcine jejunum via repair of tight junctions

PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page